dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies

Simple item page
dc.contributor.authorPalomares Gracia, Óscar
dc.contributor.authorSánchez Ramón, Silvia María
dc.contributor.authorDávila, Ignacio
dc.contributor.authorPrieto, Luis
dc.contributor.authorPérez de Llano, Luis
dc.contributor.authorLleonart, Marta
dc.contributor.authorDomingo, Christian
dc.contributor.authorNieto, Antonio
dc.date.accessioned2023-06-18T00:02:54Z
dc.date.available2023-06-18T00:02:54Z
dc.date.issued2017-06-21
dc.description.abstractAsthma is an airway disease characterised by chronic inflammation with intermittent or permanent symptoms including wheezing, shortness of breath, chest tightness, and cough, which vary in terms of their occurrence, frequency, and intensity. The most common associated feature in the airways of patients with asthma is airway inflammation. In recent decades, efforts have been made to characterise the heterogeneous clinical nature of asthma. The interest in improving the definitions of asthma phenotypes and endotypes is growing, although these classifications do not always correlate with prognosis nor are always appropriate therapeutic approaches. Attempts have been made to identify the most relevant molecular and cellular biomarkers underlying the immunopathophysiological mechanisms of the disease. For almost 50 years, immunoglobulin E (IgE) has been identified as a central factor in allergic asthma, due to its allergen-specific nature. Many of the mechanisms of the inflammatory cascade underlying allergic asthma have already been elucidated, and IgE has been shown to play a fundamental role in the triggering, development, and chronicity of the inflammatory responses within the disease. Blocking IgE with monoclonal antibodies such as omalizumab have demonstrated their efficacy, effectiveness, and safety in treating allergic asthma. A better understanding of the multiple contributions of IgE to the inflammatory continuum of asthma could contribute to the development of novel therapeutic strategies for the disease.
dc.description.departmentDepto. de Inmunología, Oftalmología y ORL
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.statuspub
dc.eprint.idhttps://eprints.ucm.es/id/eprint/66287
dc.identifier.doi10.3390/ijms18061328
dc.identifier.issn1422-0067
dc.identifier.officialurlhttps://doi.org/10.3390/ijms18061328
dc.identifier.relatedurlhttps://www.mdpi.com/1422-0067/18/6/1328
dc.identifier.urihttps://hdl.handle.net/20.500.14352/19189
dc.issue.number6
dc.journal.titleInternational Journal of Molecular Sciences
dc.language.isoeng
dc.page.initial1328
dc.publisherMDPI
dc.rightsAtribución 3.0 España
dc.rights.accessRightsopen access
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/es/
dc.subject.keywordallergy
dc.subject.keywordasthma
dc.subject.keywordimmunoglobulin E (IgE)
dc.subject.keywordbiomarkers
dc.subject.keywordimmunological mechanisms
dc.subject.keywordimmunomodulation
dc.subject.keywordbiological treatment
dc.subject.keywordanti-IgE
dc.subject.keywordomalizumab
dc.subject.ucmBiología molecular (Química)
dc.subject.ucmBioquímica (Química)
dc.subject.ucmMicrobiología médica
dc.subject.unesco3201.03 Microbiología Clínica
dc.titledIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies
dc.typejournal article
dc.volume.number18
dspace.entity.typePublication
relation.isAuthorOfPublication849d1c21-090b-4cfa-8f5b-857c7276b26d
relation.isAuthorOfPublicationbea59590-c16b-4e29-b8d6-d7b2133b4533
relation.isAuthorOfPublication.latestForDiscovery849d1c21-090b-4cfa-8f5b-857c7276b26d
Download
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijms-18-01328.pdf
Size:
3.84 MB
Format:
Adobe Portable Document Format
downoload Download
Collections
Artículos